Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

The FDA has approved Akeega plus prednisone for adults with deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer.

The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...

Using advanced computational genomics, Johns Hopkins investigators discovered how prostate cancer develops resistance to ...

Johnson & Johnson JNJ announced that the FDA approved its precision therapy, Akeega (niraparib and abiraterone acetate ...

Shares Monte Rosa Therapeutics shares were higher after the company reported positive interim data from a Phase 1/2 trial for a prostate cancer treatment. Shares were up 9.4% to $18.00 in Tuesday ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...

Older Americans with metastatic breast, colorectal, lung, or prostate cancer are spending an increasing amount of time in the ...

Treatment for Metastatic Hormone Sensitive Prostate Cancer, Talking with your Healthcare Team (Download - COMING SOON) ...

But a practice called integrative medicine, which combines conventional cancer therapies with complementary and holistic treatments, is increasingly being used to manage the disease. While ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...